Digital rendering of Arcalis' new manufacturing site in Minamisoma City, Japan.

Arc­turus Ther­a­peu­tics hand­ed $115M from Japan­ese gov­ern­ment to de­vel­op pro­duc­tion site

San Diego-based RNA biotech Arc­turus Ther­a­peu­tics’ man­u­fac­tur­ing op­er­a­tions in Japan have been giv­en a fi­nan­cial boost from the lo­cal gov­ern­ment.

Ar­calis Co., Ltd., its pro­duc­tion op­er­a­tion, is a joint ven­ture be­tween Arc­turus and Tokyo-based drug dis­cov­ery com­pa­ny Ax­ce­lead. Ar­calis has re­ceived $115 mil­lion in two grants from the Japan­ese gov­ern­ment. Ar­calis is re­spon­si­ble for man­u­fac­tur­ing mR­NA-based vac­cines and med­i­cines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.